Blood Cancer Journal

Article	Citations
Disparities in time to treatment with oral antimyeloma medications	270
Correction: Targeting of IL-10R on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells	205
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M	201
Genomic landscape of hyperleukocytic acute myeloid leukemia	137
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib	123
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort	113
Comparison of tisagenlecleucel with conventional treatments for relapsed/refractory diffuse large B-cell lymphomas: a retrospective external comparator study	96
A multiparametric niche-like drug screening platform in acute myeloid leukemia	94
BCR::ABL1-positive acute lymphoblastic leukemia as a high-risk feature of central nervous system relapse after allogeneic hematopoietic cell transplantation	93
Determinants of survival and retrospective comparisons of 183 clinical trial patients with myelofibrosis treated with momelotinib, ruxolitinib, fedratinib or BMS- 911543 JAK2 inhibitor	87
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes	82
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity	81
Real world data with concurrent retinoic acid and arsenic trioxide for the treatment of acute promyelocytic leukemia	80
Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency	74
Safety and efficacy of blinatumomab as bridge-to-transplant for B-cell acute lymphoblastic leukemia in first complete remission with no detectable minimal residual disease	74
Dynamics of microcyst-like epithelial changes associated with Belantamab mafodotin therapy in a patient with multiple myeloma—a case report	70
Prognostic impact of early NGS MRD dynamics and cytomolecular risk in newly diagnosed B-cell ALL	69
Common cardiovascular biomarkers can independently predict outcome of patients with Myelodysplastic syndromes	68
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine	64
Correspondence on: Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	61
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT	56
Phase II study of novel CXCR2 agonist and Plerixafor for rapid stem cell mobilization in patients with multiple myeloma	55
In response to: Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study	55
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma	53
BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma	53

Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma	51
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid	50
T-cell phenotype including CD57+ T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma	48
Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management	47
Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study	44
Should I stay or should I go (to transplant)? Managing insufficient responses to induction in multiple myeloma	44
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients	44
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier	44
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	43
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome	42
Assessing the performance of the Iceland screens, treats, or prevents multiple myeloma (iStopMM) model in a multicultural Bronx cohort: implications for monoclonal gammopathy of undetermined significa	41
Venetoclax plus arsenic and all-trans retinoic acid in patients with relapsed/refractory acute promyelocytic leukemia	41
RSK1 dependency in FLT3-ITD acute myeloid leukemia	40
Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studies	40
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma	39
Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review	39
Donor-derived CD19-targeted chimeric antigen receptor T cells in adult transplant recipients with relapsed/refractory acute lymphoblastic leukemia	39
The PIP4K2 inhibitor THZ-P1-2 exhibits antileukemia activity by disruption of mitochondrial homeostasis and autophagy	38
Pharmacological profiling in CLL patients during pirtobrutinib therapy and disease progression	38
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression	37
Lymphoid clonal hematopoiesis: implications for malignancy, immunity, and treatment	37
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party	36
The prevalence and outcomes of frail older adults in clinical trials in multiple myeloma: A systematic review	36
Genome profiling with targeted adaptive sampling long-read sequencing for pediatric leukemia	36
Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study	36
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity	35
Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors	35
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial	34
Characteristics and predictors of central nervous system relapse in newly diagnosed acute promyelocytic leukemia in the era of arsenic: a 13-year monocenter cohort study	34
Adult AML with NUP98 rearrangements should be stratified into adverse-risk group	34
Pirtobrutinib inhibits wild-type and mutant Bruton’s tyrosine kinase-mediated signaling in chronic lymphocytic leukemia	33
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma	33
Exploring racial disparities in treatment patterns and outcomes for patients with multiple myeloma using real world data	33
Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma	32
Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma	32
Prognostic indices in diffuse large B-cell lymphoma: a population-based comparison and validation study of multiple models	32
Bispecific antibodies in the treatment of multiple myeloma	32
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma	31
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations	31
Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis	31
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older	30
Management of chronic myeloid leukemia in 2023 – common ground and common sense	30
Extended DaraKRd: Are we enhancing outcomes by prolonging treatment?	30
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study	30
Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia	30
Venetoclax and azacitidine for molecular relapse after intensive chemotherapy in NPM1 or CBF AML: a FILO study	29
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guide	29
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group’s clinical trial E3999	29
Deep immune cell profiling in blood and bone marrow of early stage monoclonal gammopathy: an iStopMM and ECRIN-M3 collaborative study	29
Multiple myeloma as a challenging multidimensional random process: a data-driven web-based application for treatment selection	29

Risk of lymphoid malignancy associated with cancer predisposition genes	28
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)	28
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003)	28
Pure (acute) erythroid leukemia: morphology, immunophenotype, cytogenetics, mutations, treatment details, and survival data among 41 Mayo Clinic cases	28
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection	28
Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials	27
CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma	27
Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial	27
Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia	27
Smoldering multiple myeloma current treatment algorithms	26
Donor cell-derived genetic abnormalities after sex mismatched allogeneic cell transplantation: a unique challenge of donor cell leukemia	26
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage	26
Correction: TET2 deficiency promotes MDS-associated leukemogenesis	26
Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years	26
Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians	26
Coincidence of cutaneous blastic plasmacytoid dendritic cell neoplasm and myelodysplastic syndrome derived from clonal hematopoiesis	25
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial	25
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial	25
Targeting lysine demethylase 5 (KDM5) in mantle cell lymphoma	25
Primary cells from patients with adult T cell leukemia/lymphoma depend on HTLV-1 Tax expression for NF-κB activation and survival	25
Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms	24
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study	23
Fertility and parenthood in patients with acute promyelocytic leukemia treated with Arsenic Trioxide and All-Trans retinoic acid	23
Outcomes of relapse after teclistamab therapy in multiple myeloma	23
Disease characteristics and monitoring of IDH1/IDH2-mutated acute myeloid leukemia	23
Drug development in higher-risk myelodysplastic syndromes	23
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk	23
Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation	23
Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4	22
MYC-rearranged mature B-cell lymphomas in children and young adults are molecularly Burkitt Lymphoma	22
Bispecific CAR-T cells targeting CD19/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I/II trial	22
Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children’s Haematology/Oncology Group	21
Pevonedistat, a Nedd8-activating enzyme inhibitor, in combination with ibrutinib in patients with relapsed/refractory B-cell non-Hodgkin lymphoma	21
Continuously improving outcome over time after second allogeneic stem cell transplantation in relapsed acute myeloid leukemia: an EBMT registry analysis of 1540 patients	21
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation	21
Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century	21
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients	21
Reducing the risks of nuclear war—the role of health professionals	21
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy	21
Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study	20
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages	20
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?	20
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recomm	20
Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression	20
Oral decitabine cedazuridine with and without venetoclax in higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia: a propensity score–matched study	20
Establishing measurable residual disease trajectories for patients on treatment for newly diagnosed multiple myeloma as benchmark for deployment of T-cell redirection therapy	20
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes	20
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms	20
Breakthrough infections in MPN-COVID vaccinated patients	20
Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota	20
CHIP amplifies the risk of lymphoid malignancies in individuals with monoclonal B-cell lymphocytosis (MBL)	19
Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms	19
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia	19
Cutaneous manifestations of monoclonal gammopathy	19
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma	19
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities	19
Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry	19
Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms	19
Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019	19
Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation	19
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy	19
The risk of coronavirus disease 2019 (COVID-19) among individuals with monoclonal B cell lymphocytosis	18
Humoral and cellular responses after COVID-19 booster vaccination in patients recently treated with anti-CD20 antibodies	18
The constitutive activation of STAT3 gene and its mutations are at the crossroad between LGL leukemia and autoimmune disorders	18
Mendelian randomization of immune cell phenotypes to discover potential drug targets for B-cell malignancy	18
Correction: Novel humanized CD19-CAR-T (Now talicabtagene autoleucel, Tali-cel™) cells in relapsed/ refractory pediatric B-acute lymphoblastic leukemia- an open-label single-arm phase-I/Ib study	18
To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia	18
Survival trends in hematological malignancies in the Nordic countries through 50 years	18
Cardiovascular adverse events and outcomes after anti-BCMA CAR-T for relapsed and refractory multiple myeloma	18
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML	18
Validation of the revised diagnostic criteria for primary plasma cell leukemia by the Korean Multiple Myeloma Working Party	18
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation	18
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera	17
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib	17
Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis	17
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group	17
TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms	17
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study	16
Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia	16
Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison	16

Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab	16
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection	16
Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT)	16
Identification of NOTCH-driven matrisome-associated genes as prognostic indicators of multiple myeloma patient survival	16
Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience	16
Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study	16
Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia	16
Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumamab with RVD (DRVd) in t	16
CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases	15
Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index	15
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies	15
Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms	15
Transposable elements as genome regulators in normal and malignant haematopoiesis	15
Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study	15
Early growth response 1 as a key regulator of PD-L1 expression and immune evasion in extranodal NK/T-cell lymphoma	15
EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity	15
IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial	15
Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation	15
Risk of non-Hodgkin lymphoma in breast cancer survivors: a nationwide cohort study	15
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis	15
Granulocyte colony-stimulating factor plus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia: a multicenter phase 2 trial	15
Blast phase myeloproliferative neoplasm: contemporary review and 2024 treatment algorithm	15
DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation	14
Allogeneic stem cell transplantation from variant-carrying family donors leads to long-term engraftment in Telomere Biology Disorders	14
Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine–venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net	14
Resistance to targeted therapies: delving into FLT3 and IDH	14
R-CEOP as first-line treatment for anthracycline-ineligible patients with diffuse large B-cell lymphoma	14
Patient-specific computational models predict prognosis in B cell lymphoma by quantifying pro-proliferative and anti-apoptotic signatures from genetic sequencing data	14
SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma	14
The prognostic value of the MASS in a multi-center cohort of patients with newly diagnosed multiple myeloma	14
Combined MEK and JAK inhibition reduces osteopontin plasma level and bone marrow fibrosis in a myelofibrosis mouse model	14
Immunophenotypic assessment of clonal plasma cells and B-cells in bone marrow and blood in the diagnostic classification of early stage monoclonal gammopathies: an iSTOPMM study	14
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma	14
Conditional survival in multiple myeloma and impact of prognostic factors over time	14
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study	14
The expanding CML treatment landscape: an introspective commentary	14
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome	14
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia	14
Patient preferences for intervention in the setting of precursor multiple myeloma	14
An atlas of the bone marrow bone proteome in patients with dysproteinemias	14
I-OPen: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients	14
Real-world decline in survival with poor guideline adherence in chronic myeloid leukemia care	13
Mode of progression in smoldering multiple myeloma: a study of 406 patients	13
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel	13
Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States	13
Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group	13
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee	13
Utilization of real-world evidence in regulatory approvals for multiple myeloma therapies	13
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance	13
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission	13
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy	13
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study	12
Myeloid neoplasm occurrence during stable molecular remission of NPM1-mutated AML: are we facing secondary disease or AML relapse?	12
Utility of flow cytometry screening before MRD testing in multiple myeloma	12
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma	12
secDrug: a pipeline to discover novel drug combinations to kill drug-resistant multiple myeloma cells using a greedy set cover algorithm and single-cell multi-omics	12
Assessing drivers of disparate outcomes and applicability of risk stratification in a cohort of patients with myelofibrosis	12
Socioeconomic disadvantage contributes to ethnic disparities in multiple myeloma survival: a matched cohort study	12
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study	12
A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia	12
Safety and efficacy of CD22 and CD19 CAR-T bridging auto-HSCT as consolidation therapy for AYA and adult B-ALL	12
Racial differences as predictors of outcomes in young patients with multiple myeloma	12
Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma	12
Revised free light chain reference intervals enhance risk stratification in monoclonal gammopathy of undetermined significance and reduce overdiagnosis	12
Comprehensive assessment of adverse event profiles associated with bispecific antibodies in multiple myeloma	12
Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update	12
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study	12
Venetoclax ex vivo functional profiling predicts improved progression-free survival	12
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma	12
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group	12
Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation	12
Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study	12
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target	12
Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia	11
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases	11
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives	11
Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval	11
Core-binding factor acute myeloid leukemia: long-term outcome of 70 patients uniformly treated with “7+3”	11
Indolent nodal T follicular helper cell lymphomas—A case series	11
State of the art biology, progression, and clinical management of monoclonal B-cell lymphocytosis (MBL): consensus report from the Intercepting Blood Cancers Workshop Committee	11
Subclonal heterogeneity sheds light on the transformation trajectory in IGLV3-21R110 chronic lymphocytic leukemia	11
Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets	11
In vivo expression of anti-CD19/CD3 BiTE by liver-targeted AAV for the treatment of B cell malignancies	11
Impact of the kinetics of circulating anti-CD19 CAR-T cells and their populations on the outcome of DLBCL patients	11
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry	11
Is immune effector cell-associated enterocolitis a CAR T-cell lymphoproliferative disorder?	11
Venetoclax and azacitidine in untreated patients with therapy-related acute myeloid leukemia, antecedent myelodysplastic syndromes or chronic myelomonocytic leukemia	11
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial	11
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma	11
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial	11
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma	11
Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.	10
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis	10
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study	10
RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis	10